1 signal · News / RSS
Scores are directional signals derived from aggregated public data — not verified findings or investment advice. Methodology
Signal-based estimates from public data — not verified assessments. Learn more
Moderate stress signals detected across available public data.
Moderate risk indicators present across data sources.
Signals suggest mixed Q1 2026 financial performance with an EPS beat but revenue shortfall.
Patterns indicate that while Recursion Pharmaceuticals exceeded earnings expectations in Q1 2026, revenue fell short of projections, contributing to medium stress and risk levels. Confidence in these signals remains low due to limited review coverage.
What this means
Limited signals collected so far — this score may shift significantly as more data arrives.
AI-generated from public signals — may be incomplete. Based on 1 recent signal.
This summary is generated from publicly available review and signal data. It is intended as an indicative overview only and should not be used as the sole basis for employment, investment, or business decisions. Signal volume and source diversity may limit representativeness.
Earnings call transcript: Recursion Pharmaceuticals Q1 2026 results show EPS beat but revenue miss Investing.com
AI-driven drug discovery platform.
Based on 1 signal across 1 source · snapshot 12 Jun 2026
Limited — treat this score as early-stage; more data needed.
Based on 1 signal across 1 source
Scores are directional signals derived from public data — not certified assessments or recommendations. Confidence indicates data coverage, not accuracy. Learn how scores are calculated →
Derived from public sources such as news, filings, and reported events.
AI summaries are generated from public signals and may not reflect the full picture.